National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Dabigatran etexilate (Pradaxa®) – for the prevention of stroke and systematic embolisom in atrial fibrillation

Dabigatran etexilate (Pradaxa®) for the Prevention of Stroke and Systemic Embolism in Adult Patients with Atrial Fibrillation

Pharmacoeconomic Evaluation

Commenced Completed Outcome
02/11/2010 03/06/2011 Reimbursement not Recommended

Dabigatran Etexilate (Pradaxa®) summary


Following the NCPE pharmacoeconomic assessment (August 2011) the manufacturer reduced the price of dabigatran.  At this revised price we now consider dabigatran cost effective for this indication.